Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, USA.
Methods Mol Biol. 2021;2193:121-128. doi: 10.1007/978-1-0716-0845-6_12.
Critical limb ischemia (CLI) is primarily associated with a high risk of major amputation, cardiovascular events, and death. The current therapy involves direct endovascular intervention and is associated with long-term recurrence. However, patients with significant comorbidities are not eligible for this therapy. Hind limb ischemia model via femoral artery excision has commonly been used to determine therapeutic potential and for investigating cellular and molecular mechanisms. This protocol describes the ischemic model development in NOD/SCID mice and the use of human umbilical cord blood-derived and nanofiber scaffold-expanded CD34 stem cells to investigate the efficacy of regenerative therapy.
严重肢体缺血（CLI）主要与大截肢、心血管事件和死亡的高风险相关。目前的治疗方法包括直接血管内介入治疗，且存在长期复发的风险。然而，有严重合并症的患者不适合这种治疗方法。通过股动脉切除建立后肢缺血模型常用于确定治疗潜力和研究细胞和分子机制。本方案描述了 NOD/SCID 小鼠缺血模型的建立，以及使用人脐带来源的和纳米纤维支架扩增的 CD34 干细胞来研究再生治疗的效果。
